TLR9 agonist lefitolimod to improve antitumor effect of checkpoint inhibitors in vivo.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e14625
Abstract: e14625Background: TLR9 agonists are potent activators of the immune system via induction of cellular and humoral responses. Preclinical and ongoing clinical studies support the use of TLR9 agonists for immunotherapeutic approaches. Lefitolimod/MGN1703 is a covalently-closed… read more here.
Keywords: lefitolimod improve; checkpoint inhibitors; tlr9 agonist; agonist lefitolimod ... See more keywords